NICE questions new diabetes drug’s cost effectiveness
The National Institute for Health and Care Excellence has called for more evidence from Boehringer Ingelheim on its drug empagliflozin for treating type 2 diabetes.
Get unlimited access
As a subscriber you will benefit from:
- Full online and mobile access to news and opinion stories
Customised email alerts straight to your inbox (over 30 alerts available)
- 4,500 practice articles in our archive
- Over £500 worth of CPD learning units